Clinical Trials

21 enrolled

Carcinoma, Hepatocellular

NCT04834674 2026-04-07

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

NCT02867956 2026-03-10

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

35 enrolled

Ovarian Neoplasms

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

157 enrolled 17 charts

Advanced Primary Liver Cancer

NCT05235100 2025-12-11

SPARE-02

30 enrolled

Sarcoma

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Colonic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Advanced Gastric Cancer

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

93 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

25 enrolled

Stomach Neoplasms

NCT03417895 2024-08-07

PASSION

59 enrolled 17 charts

Small Cell Lung Carcinoma

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

28 enrolled

Biliary Tract Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT03267121 2023-10-17

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03180476 2023-04-14

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

21 enrolled

Nasopharyngeal Neoplasms

NCT03816553 2023-04-11

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

45 enrolled

Uterine Cervical Neoplasms

NCT01192971 2023-03-03

HCC

121 enrolled

Tumor-Agnostic

Neoplasms

NCT02976896 2023-02-16

Poetry-1

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT05025033 2023-01-18

Chemotherapy Combined With Apatinib and PD-1 Antibody

30 enrolled

Stomach Neoplasms

NCT04350190 2023-01-13

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT02945852 2022-07-19

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Small Cell Lung Carcinoma

NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

66 enrolled

Advanced Triple-Negative Breast Cancer

NCT03104283 2022-03-15

Apatinib for the Elderly Advanced Gastric Cancer

48 enrolled

Stomach Neoplasms

NCT04188847 2022-03-15

First-line Chemotherapy for Recurrent Cervical Cancer

37 enrolled

Uterine Cervical Neoplasms

NCT03243838 2022-02-02

LANCET

31 enrolled

Triple Negative Breast Neoplasms

NCT02731352 2022-01-20

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Neoplasms

NCT04047017 2021-07-30

GTN

Recurrence, Gestational Trophoblastic Disease

NCT04642664 2021-06-03

ACABC

22 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02878057 2021-01-27

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

30 enrolled 12 charts

Breast Neoplasms

NCT03274011 2021-01-26

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

NCT03251443 2020-12-02

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

34 enrolled

Cholangiocarcinoma

NCT03547804 2020-12-01

MK 01

31 enrolled

Small Cell Lung Carcinoma

NCT04338438 2020-11-10

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

37 enrolled

Stomach Neoplasms

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Breast Neoplasms

NCT03359018 2020-05-19

APFAO

43 enrolled

Sarcoma

Osteosarcoma

NCT03190616 2020-01-14

Apatinib in Refractory Colorectal Cancer

54 enrolled

Colorectal Neoplasms

NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

25 enrolled

Efficacy and Safety

NCT01176669 2015-09-09

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

60 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01531777 2015-04-03

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Colorectal Neoplasms

NCT01653561 2013-12-03

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Breast Neoplasms

NCT01270386 2012-02-10

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

136 enrolled